Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07423494 · ClinicalTrials.gov registry record · Phase 1
Personalized Antisense Oligonucleotide Therapy for A Single Patient With CHCHD10 ALS (nL18576)
A Phase 1 study, sponsored by n-Lorem Foundation.
- Not yet
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT07423494: Clinical Trial Phase 1 study, sponsored by n-Lorem Foundation.
NCT07423494 is a Phase 1 study that has not yet begun recruiting, run by n-Lorem Foundation. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07423494, a Phase 1 study, has not yet begun recruiting, sponsored by n-Lorem Foundation.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in CHCHD10
Primary Outcome
Change from baseline at 12-months post nL-CHCHD-001 administration in scores on Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R).
Interventions
- DRUG nL-CHCHD-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2026-03 |
| Est. Completion | 2027-03 |
| Phase | Phase 1 |
What is known before NCT07423494 opens enrollment
NCT07423494 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which nL-CHCHD-001 is the first listed.
NCT07423494 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07423494 about?
NCT07423494 is a clinical study titled "Personalized Antisense Oligonucleotide Therapy for A Single Patient With CHCHD10 ALS (nL18576)". This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in CHCHD10
What is the current status of trial NCT07423494?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2026-03. Estimated completion is 2027-03.
What interventions are being tested in trial NCT07423494?
The interventions under investigation include: nL-CHCHD-001 (DRUG).
Who is sponsoring clinical trial NCT07423494?
This trial is sponsored by n-Lorem Foundation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07423494's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia